BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Aljiffry M, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of cholangiocarcinoma: 1990-2009. World J Gastroenterol 2009; 15(34): 4240-4262 [PMID: 19750567 DOI: 10.3748/wjg.15.4240] [Cited by in CrossRef: 175] [Cited by in F6Publishing: 157] [Article Influence: 14.6] [Reference Citation Analysis]
Number Citing Articles
1 Grendar J, Grendarova P, Sinha R, Dixon E. Neoadjuvant therapy for downstaging of locally advanced hilar cholangiocarcinoma: a systematic review. HPB (Oxford) 2014;16:297-303. [PMID: 23981000 DOI: 10.1111/hpb.12150] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
2 Kiefer MV, Albert M, Mcnally M, Robertson M, Sun W, Fraker D, Olthoff K, Christians K, Pappas S, Rilling W, Soulen MC. Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvinyl alcohol: A 2-center study. Cancer 2011;117:1498-505. [DOI: 10.1002/cncr.25625] [Cited by in Crossref: 88] [Cited by in F6Publishing: 76] [Article Influence: 8.0] [Reference Citation Analysis]
3 Schlitter AM, Esposito I. Definition of microscopic tumor clearance (r0) in pancreatic cancer resections. Cancers (Basel). 2010;2:2001-2010. [PMID: 24281214 DOI: 10.3390/cancers2042001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.6] [Reference Citation Analysis]
4 Gu J, Bai J, Shi X, Zhou J, Qiu Y, Wu Y, Jiang C, Sun X, Xu F, Zhang Y. Efficacy and safety of liver transplantation in patients with cholangiocarcinoma: a systematic review and meta-analysis. Int J Cancer. 2012;130:2155-2163. [PMID: 21387295 DOI: 10.1002/ijc.26019] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
5 Azoulay D, Pascal G, Salloum C, Adam R, Castaing D, Tranecol N. Vascular reconstruction combined with liver resection for malignant tumours. Br J Surg. 2013;100:1764-1775. [PMID: 24227362 DOI: 10.1002/bjs.9295] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 4.6] [Reference Citation Analysis]
6 Chen MH, Liang PC, Chang KC, Huang JY, Chang YT, Chang FY, Wong JM, Lin FH. Prototype of biliary drug-eluting stent with photodynamic and chemotherapy using electrospinning. Biomed Eng Online 2014;13:118. [PMID: 25138739 DOI: 10.1186/1475-925X-13-118] [Cited by in Crossref: 5] [Article Influence: 0.7] [Reference Citation Analysis]
7 Massani M, Bonariol L, Stecca T. Hepatic Arterial Infusion Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma, a Comprehensive Review. J Clin Med 2021;10:2552. [PMID: 34207700 DOI: 10.3390/jcm10122552] [Reference Citation Analysis]
8 Kabbach G, Assi HA, Bolotin G, Schuster M, Lee HJ, Tadros M. Hepatobiliary Tumors: Update on Diagnosis and Management. J Clin Transl Hepatol 2015;3:169-81. [PMID: 26623263 DOI: 10.14218/JCTH.2015.00012] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
9 Choi H, Shin O, Kim H, Jeon B, Park Y, Kim S, Kim S, Chae H, Lee SV. Efficacy of Endobiliary Radiofrequency Ablation using a Novel Endoluminal Radiofrequency Ablation Catheter in a Swine Model. Journal of Investigative Surgery 2019;32:731-7. [DOI: 10.1080/08941939.2018.1489566] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 Han K, Ko HK, Kim KW, Won HJ, Shin YM, Kim PN. Radiofrequency Ablation in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-Analysis. Journal of Vascular and Interventional Radiology 2015;26:943-8. [DOI: 10.1016/j.jvir.2015.02.024] [Cited by in Crossref: 55] [Cited by in F6Publishing: 93] [Article Influence: 9.2] [Reference Citation Analysis]
11 Nanda A, Brown JM, Berger SH, Lewis MM, Barr Fritcher EG, Gores GJ, Keilin SA, Woods KE, Cai Q, Willingham FF. Triple modality testing by endoscopic retrograde cholangiopancreatography for the diagnosis of cholangiocarcinoma. Therap Adv Gastroenterol. 2015;8:56-65. [PMID: 25729431 DOI: 10.1177/1756283x14564674] [Cited by in Crossref: 42] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
12 Boland B, Kim A, Nissen N, Colquhoun S. Cholangiocarcinoma: Aggressive Surgical Intervention Remains Justified. The American Surgeon 2012;78:157-60. [DOI: 10.1177/000313481207800231] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 O'Hara SP, Gradilone SA, Masyuk TV, Tabibian JH, LaRusso NF. MicroRNAs in Cholangiopathies. Curr Pathobiol Rep 2014;2:133-42. [PMID: 25097819 DOI: 10.1007/s40139-014-0048-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
14 Conrad R, Castelino-Prabhu S, Cobb C, Raza A. Cytopathologic diagnosis of liver mass lesions. J Gastrointest Oncol 2013;4:53-61. [PMID: 23450205 DOI: 10.3978/j.issn.2078-6891.2012.020] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
15 Hwang IG, Song HS, Lee MA, Nam EM, Lim J, Lee KH, Lee KT, Zang DY, Jang J. Treatment outcomes of gemcitabine alone versus gemcitabine plus platinum for advanced biliary tract cancer: a Korean Cancer Study Group retrospective analysis. Cancer Chemother Pharmacol 2014;74:1291-6. [DOI: 10.1007/s00280-014-2608-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
16 Zhou MH, Zhou HW, Liu M, Sun JZ. The role of miR-92b in cholangiocarcinoma patients. Int J Biol Markers 2018;33:293-300. [PMID: 29749758 DOI: 10.1177/1724600817751524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
17 Zhu GQ, Shi KQ, You J, Zou H, Lin YQ, Wang LR, Braddock M, Chen YP, Zheng MH. Systematic review with network meta-analysis: adjuvant therapy for resected biliary tract cancer. Aliment Pharmacol Ther. 2014;40:759-770. [PMID: 25099956 DOI: 10.1111/apt.12900] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
18 Suksawat M, Klanrit P, Phetcharaburanin J, Namwat N, Khuntikeo N, Titapun A, Jarearnrat A, Sa-Ngiamwibool P, Techasen A, Loilome W. In vitro and molecular chemosensitivity in human cholangiocarcinoma tissues. PLoS One 2019;14:e0222140. [PMID: 31504065 DOI: 10.1371/journal.pone.0222140] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
19 Yu WL, Cong WM, Zhang Y, Chen Y, Wang F, Yu G. Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilar cholangiocarcinoma. J Surg Res 2011;171:663-8. [PMID: 20605601 DOI: 10.1016/j.jss.2010.03.049] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.7] [Reference Citation Analysis]
20 Akamatsu N, Sugawara Y, Hashimoto D. Surgical strategy for bile duct cancer: Advances and current limitations. World J Clin Oncol 2011; 2(2): 94-107 [PMID: 21603318 DOI: 10.5306/wjco.v2.i2.94] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
21 Liang Z, Liu X, Zhang Q, Wang C, Zhao Y. Diagnostic value of microRNAs as biomarkers for cholangiocarcinoma. Dig Liver Dis. 2016;48:1227-1232. [PMID: 27476468 DOI: 10.1016/j.dld.2016.07.006] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
22 Clawson KA, Borja-Cacho D, Antonoff MB, Saluja AK, Vickers SM. Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J Surg Res 2010;163:244-9. [PMID: 20691980 DOI: 10.1016/j.jss.2010.03.067] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
23 Schiffman SC, Metzger T, Dubel G, Andrasina T, Kralj I, Tatum C, McMasters KM, Scoggins CR, Martin RC. Precision hepatic arterial irinotecan therapy in the treatment of unresectable intrahepatic cholangiocellular carcinoma: optimal tolerance and prolonged overall survival. Ann Surg Oncol. 2011;18:431-438. [PMID: 20862554 DOI: 10.1245/s10434-010-1333-4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
24 Kiesslich T, Neureiter D, Wolkersdörfer GW, Plaetzer K, Berr F. Advances in photodynamic therapy for the treatment of hilar biliary tract cancer. Future Oncol 2010;6:1925-36. [PMID: 21142865 DOI: 10.2217/fon.10.147] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
25 Gentilini A, Pastore M, Marra F, Raggi C. The Role of Stroma in Cholangiocarcinoma: The Intriguing Interplay between Fibroblastic Component, Immune Cell Subsets and Tumor Epithelium. Int J Mol Sci. 2018;19. [PMID: 30249019 DOI: 10.3390/ijms19102885] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
26 Andersen JB, Spee B, Blechacz BR, Avital I, Komuta M, Barbour A, Conner EA, Gillen MC, Roskams T, Roberts LR. Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors. Gastroenterology. 2012;142:1021-1031.e15. [PMID: 22178589 DOI: 10.1053/j.gastro.2011.12.005] [Cited by in Crossref: 272] [Cited by in F6Publishing: 304] [Article Influence: 27.2] [Reference Citation Analysis]
27 Xu J, Li D, Li X, Liu Z, Li T, Jiang P, He Q, Tian F, Gao Y, Wang D, Wang S. 67 laminin receptor promotes the malignant potential of tumour cells up-regulating lysyl oxidase-like 2 expression in cholangiocarcinoma. Digestive and Liver Disease 2014;46:750-7. [DOI: 10.1016/j.dld.2014.03.017] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
28 Lee BS, Cha BH, Park EC, Roh J. Risk factors for perihilar cholangiocarcinoma: a hospital-based case-control study. Liver Int 2015;35:1048-53. [PMID: 24923595 DOI: 10.1111/liv.12618] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 2.7] [Reference Citation Analysis]
29 Kim GH, Kim PH, Kim JH, Kim PN, Won HJ, Shin YM, Choi SH. Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis. Eur Radiol 2021. [PMID: 34347159 DOI: 10.1007/s00330-021-08216-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Sumiyoshi T, Shima Y, Okabayashi T, Negoro Y, Shimada Y, Iwata J, Matsumoto M, Hata Y, Noda Y, Sui K, Sueda T. Chemoradiotherapy for Initially Unresectable Locally Advanced Cholangiocarcinoma. World J Surg. 2018;42:2910-2918. [PMID: 29511872 DOI: 10.1007/s00268-018-4558-1] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
31 Massani M, Stecca T, Pauletti B, Marte G, Ruffolo C, Bonariol L, Bassi N. Intrahepatic Cholangiocarcinoma. In: Abdeldayem H, editor. Topics in the Surgery of the Biliary Tree. InTech; 2018. [DOI: 10.5772/intechopen.75516] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
32 Huang DW, Huang M, Lin XS, Huang Q. CD155 expression and its correlation with clinicopathologic characteristics, angiogenesis, and prognosis in human cholangiocarcinoma. Onco Targets Ther 2017;10:3817-25. [PMID: 28814880 DOI: 10.2147/OTT.S141476] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 4.8] [Reference Citation Analysis]
33 Gatto M, Alvaro D. New insights on cholangiocarcinoma. World J Gastrointest Oncol 2010; 2(3): 136-145 [PMID: 21160821 DOI: 10.4251/wjgo.v2.i3.136] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 37] [Article Influence: 3.8] [Reference Citation Analysis]
34 Park SY, Kim JH, Won HJ, Shin YM, Kim PN. Radiofrequency ablation of hepatic metastases after curative resection of extrahepatic cholangiocarcinoma. AJR Am J Roentgenol 2011;197:W1129-34. [PMID: 22109330 DOI: 10.2214/AJR.11.6420] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
35 Zhao H, Yang F, Zhao W, Zhang C, Liu J. Fascin Overexpression Promotes Cholangiocarcinoma RBE Cell Proliferation, Migration, and Invasion. Technol Cancer Res Treat 2016;15:322-33. [PMID: 25882880 DOI: 10.1177/1533034615580696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
36 Guo L, Zhou Y, Chen Y, Sun H, Wang Y, Qu Y. LncRNA ASAP1-IT1 positively modulates the development of cholangiocarcinoma via hedgehog signaling pathway. Biomed Pharmacother 2018;103:167-73. [PMID: 29653361 DOI: 10.1016/j.biopha.2018.04.015] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 4.7] [Reference Citation Analysis]
37 Wijlemans JW, Van Erpecum KJ, Lam MG, Seinstra BA, Smits ML, Zonnenberg BA, Van Den Bosch MA. Trans-arterial 90yttrium radioembolization for patients with unresectable tumors originating from the biliary tree. Annals of Hepatology 2011;10:349-54. [DOI: 10.1016/s1665-2681(19)31549-2] [Cited by in Crossref: 7] [Article Influence: 0.7] [Reference Citation Analysis]
38 Flood TA, Jain D, Marginean EC. Malignant tumours of gallbladder and extrahepatic bile ducts. Diagnostic Histopathology 2010;16:360-70. [DOI: 10.1016/j.mpdhp.2010.06.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
39 Rompianesi G, Di Martino M, Gordon-Weeks A, Montalti R, Troisi R. Liquid biopsy in cholangiocarcinoma: Current status and future perspectives. World J Gastrointest Oncol 2021; 13(5): 332-350 [PMID: 34040697 DOI: 10.4251/wjgo.v13.i5.332] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
40 Schiffman SC, Nowacki MR, Spencer L, Mcmasters KM, Scoggins CR, Martin RC. Molecular factors associated with recurrence and survival following hepatectomy in patients with intrahepatic cholangiocarcinoma: A guide to adjuvant clinical trials: Molecular Factors Associated with Recurrence and Survival. J Surg Oncol 2014;109:98-103. [DOI: 10.1002/jso.23459] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
41 Sommer CM, Kauczor HU, Pereira PL. Locoregional Therapies of Cholangiocarcinoma. Visc Med 2016;32:414-20. [PMID: 28229076 DOI: 10.1159/000453010] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 2.4] [Reference Citation Analysis]
42 Grunnet M, Mau-Sørensen M. Serum tumor markers in bile duct cancer--a review.Biomarkers. 2014;19:437-443. [PMID: 24857368 DOI: 10.3109/1354750X.2014.923048] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 3.9] [Reference Citation Analysis]
43 Huang Y, Li X, Zhao Y. Progression of targeted therapy in advanced cholangiocarcinoma. Chin J Cancer Res. 2015;27:122-127. [PMID: 25937773 DOI: 10.3978/j.issn.1000-9604.2015.04.01] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
44 Habermehl D, Lindel K, Rieken S, Haase K, Goeppert B, Büchler MW, Schirmacher P, Welzel T, Debus J, Combs SE. Chemoradiation in patients with unresectable extrahepatic and hilar cholangiocarcinoma or at high risk for disease recurrence after resection : Analysis of treatment efficacy and failure in patients receiving postoperative or primary chemoradiation. Strahlenther Onkol 2012;188:795-801. [PMID: 22526232 DOI: 10.1007/s00066-012-0099-y] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
45 Dimitroulis D, Tsaparas P, Valsami S, Mantas D, Spartalis E, Markakis C, Kouraklis G. Indications, limitations and maneuvers to enable extended hepatectomy: Current trends. World J Gastroenterol 2014; 20(24): 7887-7893 [PMID: 24976725 DOI: 10.3748/wjg.v20.i24.7887] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
46 Gradilone SA, O'Hara SP, Masyuk TV, Pisarello MJ, LaRusso NF. MicroRNAs and benign biliary tract diseases. Semin Liver Dis 2015;35:26-35. [PMID: 25632932 DOI: 10.1055/s-0034-1397346] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
47 Kim YH, Hong EK, Kong SY, Han SS, Kim SH, Rhee JK, Hwang SK, Park SJ, Kim TM. Two classes of intrahepatic cholangiocarcinoma defined by relative abundance of mutations and copy number alterations. Oncotarget 2016;7:23825-36. [PMID: 27009864 DOI: 10.18632/oncotarget.8183] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
48 Promraksa B, Katrun P, Phetcharaburanin J, Kittirat Y, Namwat N, Techasen A, Li JV, Loilome W. Metabolic Changes of Cholangiocarcinoma Cells in Response to Coniferyl Alcohol Treatment. Biomolecules 2021;11:476. [PMID: 33810184 DOI: 10.3390/biom11030476] [Reference Citation Analysis]
49 Okusaka T, Nakachi K, Fukutomi A, Mizuno N, Ohkawa S, Funakoshi A, Nagino M, Kondo S, Nagaoka S, Funai J, Koshiji M, Nambu Y, Furuse J, Miyazaki M, Nimura Y. Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan. Br J Cancer. 2010;103:469-474. [PMID: 20628385 DOI: 10.1038/sj.bjc.6605779] [Cited by in Crossref: 375] [Cited by in F6Publishing: 382] [Article Influence: 34.1] [Reference Citation Analysis]
50 Cao K, Li B, Zhang YW, Song H, Chen YG, Gong YJ, Li HY, Zuo S. miR-29b restrains cholangiocarcinoma progression by relieving DNMT3B-mediated repression of CDKN2B expression. Aging (Albany NY) 2021;13:6055-65. [PMID: 33601338 DOI: 10.18632/aging.202549] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Park SY, Kim JH, Yoon HJ, Lee IS, Yoon HK, Kim KP. Transarterial chemoembolization vs supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol. 2011;66:322-328. [PMID: 21356394 DOI: 10.1016/j.crad.2010.11.002] [Cited by in Crossref: 87] [Cited by in F6Publishing: 126] [Article Influence: 8.7] [Reference Citation Analysis]
52 Witjes CD, Karim-Kos HE, Visser O, de Vries E, IJzermans JN, de Man RA, Coebergh JW, Verhoef C. Intrahepatic cholangiocarcinoma in a low endemic area: rising incidence and improved survival. HPB (Oxford). 2012;14:777-781. [PMID: 23043667 DOI: 10.1111/j.1477-2574.2012.00536.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
53 Higashi M, Yamada N, Yokoyama S, Kitamoto S, Tabata K, Koriyama C, Batra SK, Yonezawa S. Pathobiological Implications of MUC16/CA125 Expression in Intrahepatic Cholangiocarcinoma-Mass Forming Type. Pathobiology 2012;79:101-6. [DOI: 10.1159/000335164] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 3.6] [Reference Citation Analysis]
54 Yoon SO, Jeon TJ, Park JS, Ryu YH, Lee JH, Yoo JS, Kim JK, Yoon DS, Oh EJ. Analysis of the roles of glucose transporter 1 and hexokinase 2 in the metabolism of glucose by extrahepatic bile duct cancer cells. Clin Nucl Med 2015;40:e178-82. [PMID: 25608150 DOI: 10.1097/RLU.0000000000000640] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
55 Gadaleta CD, Ranieri G. Trans-arterial chemoembolization as a therapy for liver tumours: New clinical developments and suggestions for combination with angiogenesis inhibitors. Crit Rev Oncol Hematol. 2011;80:40-53. [PMID: 21067940 DOI: 10.1016/j.critrevonc.2010.10.005] [Cited by in Crossref: 44] [Cited by in F6Publishing: 45] [Article Influence: 4.0] [Reference Citation Analysis]
56 Goenka MK, Goenka U. Palliation: Hilar cholangiocarcinoma. World J Hepatol 2014; 6(8): 559-569 [PMID: 25232449 DOI: 10.4254/wjh.v6.i8.559] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
57 Madhusudhan KS, Gamanagatti S, Gupta AK. Imaging and interventions in hilar cholangiocarcinoma: A review. World J Radiol 2015; 7(2): 28-44 [PMID: 25729485 DOI: 10.4329/wjr.v7.i2.28] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
58 Reitz S, Slam K, Chambers LW. Biliary, pancreatic, and hepatic imaging for the general surgeon. Surg Clin North Am. 2011;91:59-92. [PMID: 21184901 DOI: 10.1016/j.suc.2010.10.005] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
59 Li M, Bai M, Qi X, Li K, Yin Z, Wang J, Wu W, Zhen L, He C, Fan D. Percutaneous transhepatic biliary metal stent for malignant hilar obstruction: results and predictive factors for efficacy in 159 patients from a single center. Cardiovasc Intervent Radiol. 2015;38:709-721. [PMID: 25338831 DOI: 10.1007/s00270-014-0992-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 3.1] [Reference Citation Analysis]
60 Rauchfuss F, Scheuerlein H, Götz M, Dittmar Y, Voigt R, Heise M, Settmacher U. [Hepatocellular carcinoma and cholangiocarcinoma]. Chirurg 2010;81:941-52; quiz 953. [PMID: 20827454 DOI: 10.1007/s00104-009-1864-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
61 Sperling J, Justinger C, Schuld J, Ziemann C, Seidel R, Kollmar O. Intrahepatic cholangiocarcinoma in a transplant liver--selective internal radiation therapy followed by right hemihepatectomy: report of a case. World J Surg Oncol 2014;12:198. [PMID: 24980217 DOI: 10.1186/1477-7819-12-198] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
62 Janthamala S, Jusakul A, Kongpetch S, Kimawaha P, Klanrit P, Loilome W, Namwat N, Techasen A. Arctigenin inhibits cholangiocarcinoma progression by regulating cell migration and cell viability via the N-cadherin and apoptosis pathway. Naunyn Schmiedebergs Arch Pharmacol 2021. [PMID: 34283274 DOI: 10.1007/s00210-021-02123-0] [Reference Citation Analysis]
63 Sohal DP, Mykulowycz K, Uehara T, Teitelbaum UR, Damjanov N, Giantonio BJ, Carberry M, Wissel P, Jacobs-Small M, O’Dwyer PJ. A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma. Ann Oncol. 2013;24:3061-3065. [PMID: 24146220 DOI: 10.1093/annonc/mdt416] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
64 Cereda S, Belli C, Reni M. Adjuvant treatment in biliary tract cancer: To treat or not to treat? World J Gastroenterol 2012; 18(21): 2591-2596 [PMID: 22690066 DOI: 10.3748/wjg.v18.i21.2591] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
65 Romani AA, Desenzani S, Morganti MM, Baroni MC, Borghetti AF, Soliani P. The BH3-mimetic ABT-737 targets the apoptotic machinery in cholangiocarcinoma cell lines resulting in synergistic interactions with zoledronic acid. Cancer Chemother Pharmacol. 2011;67:557-567. [PMID: 20473610 DOI: 10.1007/s00280-010-1345-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
66 Högberg J, Rizell M, Hultborn R, Svensson J, Henrikson O, Mölne J, Gjertsson P, Bernhardt P. Heterogeneity of microsphere distribution in resected liver and tumour tissue following selective intrahepatic radiotherapy. EJNMMI Res 2014;4:48. [PMID: 26116112 DOI: 10.1186/s13550-014-0048-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
67 Dasanu CA, Majumder S, Trikudanathan G. Emerging pharmacotherapeutic strategies for cholangiocarcinoma. Expert Opinion on Pharmacotherapy 2011;12:1865-74. [DOI: 10.1517/14656566.2011.583919] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
68 Raggi C, Fiaccadori K, Pastore M, Correnti M, Piombanti B, Forti E, Navari N, Abbadessa G, Hall T, Destro A, Di Tommaso L, Roncalli M, Meng F, Glaser S, Rovida E, Peraldo-Neia C, Olaizola P, Banales JM, Gerussi A, Elvevi A, Droz Dit Busset M, Bhoori S, Mazzaferro V, Alpini G, Marra F, Invernizzi P. Antitumor Activity of a Novel Fibroblast Growth Factor Receptor Inhibitor for Intrahepatic Cholangiocarcinoma. Am J Pathol 2019;189:2090-101. [PMID: 31351075 DOI: 10.1016/j.ajpath.2019.06.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
69 Boškoski I, Schepis T, Tringali A, Familiari P, Bove V, Attili F, Landi R, Perri V, Costamagna G. Personalized Endoscopy in Complex Malignant Hilar Biliary Strictures. J Pers Med 2021;11:78. [PMID: 33572913 DOI: 10.3390/jpm11020078] [Reference Citation Analysis]
70 Bartolini I, Risaliti M, Fortuna L, Agostini C, Ringressi MN, Taddei A, Muiesan P. Current management of intrahepatic cholangiocarcinoma: from resection to palliative treatments. Radiol Oncol 2020;54:263-71. [PMID: 32726292 DOI: 10.2478/raon-2020-0045] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
71 Huang GL, Luo Q, Rui G, Zhang W, Zhang QY, Chen QX, Shen DY. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma. Mol Cell Biol. 2013;33:3416-3425. [PMID: 23798555 DOI: 10.1128/mcb.00384-13] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
72 Ngernyuang N, Seubwai W, Daduang S, Boonsiri P, Limpaiboon T, Daduang J. Targeted delivery of 5-fluorouracil to cholangiocarcinoma cells using folic acid as a targeting agent. Mater Sci Eng C Mater Biol Appl 2016;60:411-5. [PMID: 26706547 DOI: 10.1016/j.msec.2015.11.062] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
73 Wang Y, Wu N, Luo X, Zhang X, Liao Q, Wang J. SOX2OT, a novel tumor-related long non-coding RNA. Biomed Pharmacother 2020;123:109725. [PMID: 31865145 DOI: 10.1016/j.biopha.2019.109725] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
74 Sun H, Li Y, Kong H, Dai S, Qian H. Dysregulation of KCNQ1OT1 promotes cholangiocarcinoma progression via miR-140-5p/SOX4 axis. Arch Biochem Biophys 2018;658:7-15. [PMID: 30243712 DOI: 10.1016/j.abb.2018.09.019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
75 Onori P, Gaudio E, Franchitto A, Alpini G, Francis H. Histamine regulation of hyperplastic and neoplastic cell growth in cholangiocytes. World J Gastrointest Pathophysiol 2010; 1(2): 38-49 [PMID: 21607141 DOI: 10.4291/wjgp.v1.i2.38] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
76 Fisher SB, Patel SH, Kooby DA, Weber S, Bloomston M, Cho C, Hatzaras I, Schmidt C, Winslow E, Staley CA 3rd, Maithel SK. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis. HPB (Oxford). 2012;14:514-522. [PMID: 22762399 DOI: 10.1111/j.1477-2574.2012.00489.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 4.8] [Reference Citation Analysis]
77 Zender L, Malek NP. [Diagnostics and treatment of cholangiocellular carcinoma]. Internist (Berl) 2016;57:1191-205. [PMID: 27822622 DOI: 10.1007/s00108-016-0128-5] [Reference Citation Analysis]
78 Bertani H, Frazzoni M, Mangiafico S, Caruso A, Manno M, Mirante VG, Pigò F, Barbera C, Manta R, Conigliaro R. Cholangiocarcinoma and malignant bile duct obstruction: A review of last decades advances in therapeutic endoscopy. World J Gastrointest Endosc 2015; 7(6): 582-592 [PMID: 26078827 DOI: 10.4253/wjge.v7.i6.582] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
79 Kim JH, Won HJ, Shin YM, Kim PN, Lee SG, Hwang S. Radiofrequency ablation for recurrent intrahepatic cholangiocarcinoma after curative resection. Eur J Radiol. 2011;80:e221-e225. [PMID: 20950977 DOI: 10.1016/j.ejrad.2010.09.019] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
80 Kozaka K, Kobayashi S, Takamura H, Sato Y, Kitao A, Inoue D, Yoneda N, Tajima H, Kinuya S, Harada K, Ohta T, Koda W, Matsui O, Gabata T. Differences in 18F-FDG Uptake and Expression of Glucose Transporter Between 2 Distinct Subtypes of Mass-Forming Intrahepatic Cholangiocarcinomas. Clin Nucl Med 2020;45:e267-73. [PMID: 32366791 DOI: 10.1097/RLU.0000000000003055] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
81 Ayé Soukhathammavong P, Vonghachack Y, Hatz C, Akkhavong K, Odermatt P. Suspected cases of cholangiocarcinoma seen in reference hospitals in Lao People's Democratic Republic. Parasitol Int 2017;66:510-4. [PMID: 27965165 DOI: 10.1016/j.parint.2016.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
82 Yam BL, Siegelman ES. MR imaging of the biliary system. Radiol Clin North Am. 2014;52:725-755. [PMID: 24889169 DOI: 10.1016/j.rcl.2014.02.011] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
83 Wirasorn K, Ngamprasertchai T, Chindaprasirt J, Sookprasert A, Khantikaew N, Pakkhem A, Ungarereevittaya P. Prognostic factors in resectable cholangiocarcinoma patients: Carcinoembryonic antigen, lymph node, surgical margin and chemotherapy. World J Gastrointest Oncol 2013; 5(4): 81-87 [PMID: 23671735 DOI: 10.4251/wjgo.v5.i4.81] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
84 Liu B, Yan S, Jia Y, Ma J, Wu S, Xu Y, Shang M, Mao A. TLR2 promotes human intrahepatic cholangiocarcinoma cell migration and invasion by modulating NF-κB pathway-mediated inflammatory responses. FEBS J 2016;283:3839-50. [DOI: 10.1111/febs.13894] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
85 Cadamuro M, Stecca T, Brivio S, Mariotti V, Fiorotto R, Spirli C, Strazzabosco M, Fabris L. The deleterious interplay between tumor epithelia and stroma in cholangiocarcinoma. Biochim Biophys Acta Mol Basis Dis 2018;1864:1435-43. [PMID: 28757170 DOI: 10.1016/j.bbadis.2017.07.028] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
86 Hennedige TP, Neo WT, Venkatesh SK. Imaging of malignancies of the biliary tract- an update. Cancer Imaging 2014;14:14. [PMID: 25608662 DOI: 10.1186/1470-7330-14-14] [Cited by in F6Publishing: 25] [Reference Citation Analysis]
87 Li ZH, Tang QB, Wang J, Zhou L, Huang WL, Liu RY, Chen RF. Hepatitis C virus core protein induces malignant transformation of biliary epithelial cells by activating nuclear factor-kappaB pathway. J Gastroenterol Hepatol. 2010;25:1315-1320. [PMID: 20594262 DOI: 10.1111/j.1440-1746.2009.06201.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
88 Wang N, Zhang C, Wang W, Liu J, Yu Y, Li Y, Zhang M, Ge X, Li Q, Miao L. Long noncoding RNA DANCR regulates proliferation and migration by epigenetically silencing FBP1 in tumorigenesis of cholangiocarcinoma. Cell Death Dis 2019;10:585. [PMID: 31383847 DOI: 10.1038/s41419-019-1810-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
89 Sejpal D. Advancements in biliary stenting. J Clin Gastroenterol 2012;46:191-6. [PMID: 22327303 DOI: 10.1097/MCG.0b013e3182410367] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
90 Polistina FA, Guglielmi R, Baiocchi C, Francescon P, Scalchi P, Febbraro A, Costantin G, Ambrosino G. Chemoradiation treatment with gemcitabine plus stereotactic body radiotherapy for unresectable, non-metastatic, locally advanced hilar cholangiocarcinoma. Results of a five year experience. Radiother Oncol. 2011;99:120-123. [PMID: 21621289 DOI: 10.1016/j.radonc.2011.05.016] [Cited by in Crossref: 53] [Cited by in F6Publishing: 43] [Article Influence: 5.3] [Reference Citation Analysis]
91 Höblinger A, Gerhardt T, Gonzalez-Carmona MA, Hüneburg R, Sauerbruch T, Schmitz V. Feasibility and safety of long-term photodynamic therapy (PDT) in the palliative treatment of patients with hilar cholangiocarcinoma. Eur J Med Res 2011;16:391-5. [PMID: 22024438 DOI: 10.1186/2047-783x-16-9-391] [Cited by in Crossref: 23] [Cited by in F6Publishing: 2] [Article Influence: 2.6] [Reference Citation Analysis]
92 Payne SJ, Stebbing J, Wilson P, Slater S. Outcomes in unresectable and locally advanced resected cholangiocarcinoma. Expert Rev Anticancer Ther 2011;11:705-9. [PMID: 21554045 DOI: 10.1586/era.11.32] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
93 Liu XF, Jiang H, Zhang CS, Yu SP, Wang ZQ, Su HL. Targeted drug regulation on methylation of p53-BAX mitochondrial apoptosis pathway affects the growth of cholangiocarcinoma cells. J Int Med Res 2012;40:67-75. [PMID: 22429346 DOI: 10.1177/147323001204000107] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
94 Furuse J, Okusaka T, Bridgewater J, Taketsuna M, Wasan H, Koshiji M, Valle J. Lessons from the comparison of two randomized clinical trials using gemcitabine and cisplatin for advanced biliary tract cancer. Crit Rev Oncol Hematol. 2011;80:31-39. [PMID: 21094052 DOI: 10.1016/j.critrevonc.2010.10.009] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
95 Hyder O, Marsh JW, Salem R, Petre EN, Kalva S, Liapi E, Cosgrove D, Neal D, Kamel I, Zhu AX, Sofocleous CT, Geschwind JF, Pawlik TM. Intra-arterial therapy for advanced intrahepatic cholangiocarcinoma: a multi-institutional analysis. Ann Surg Oncol. 2013;20:3779-3786. [PMID: 23846786 DOI: 10.1245/s10434-013-3127-y] [Cited by in Crossref: 74] [Cited by in F6Publishing: 118] [Article Influence: 9.3] [Reference Citation Analysis]
96 Squadroni M, Tondulli L, Gatta G, Mosconi S, Beretta G, Labianca R. Cholangiocarcinoma. Crit Rev Oncol Hematol. 2017;116:11-31. [PMID: 28693792 DOI: 10.1016/j.critrevonc.2016.11.012] [Cited by in Crossref: 51] [Cited by in F6Publishing: 49] [Article Influence: 10.2] [Reference Citation Analysis]
97 Brito AF, Abrantes AM, Encarnação JC, Tralhão JG, Botelho MF. Cholangiocarcinoma: from molecular biology to treatment. Med Oncol 2015;32:245. [PMID: 26427701 DOI: 10.1007/s12032-015-0692-x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
98 Kingham TP, Aveson VG, Wei AC, Castellanos JA, Allen PJ, Nussbaum DP, Hu Y, D'Angelica MI. Surgical management of biliary malignancy. Curr Probl Surg 2021;58:100854. [PMID: 33531120 DOI: 10.1016/j.cpsurg.2020.100854] [Reference Citation Analysis]
99 Furuse J, Okusaka T. Targeted therapy for biliary tract cancer. Cancers (Basel) 2011;3:2243-54. [PMID: 24212807 DOI: 10.3390/cancers3022243] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
100 Yazici C, Niemeyer DJ, Iannitti DA, Russo MW. Hepatocellular carcinoma and cholangiocarcinoma: an update. Expert Review of Gastroenterology & Hepatology 2013;8:63-82. [DOI: 10.1586/17474124.2014.852468] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
101 Guro H, Kim JW, Choi Y, Cho JY, Yoon YS, Han HS. Multidisciplinary management of intrahepatic cholangiocarcinoma: Current approaches. Surg Oncol 2017;26:146-52. [PMID: 28577720 DOI: 10.1016/j.suronc.2017.03.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 23] [Article Influence: 7.5] [Reference Citation Analysis]
102 Akazawa Y, Mizuno S, Fujinami N, Suzuki T, Yoshioka Y, Ochiya T, Nakamoto Y, Nakatsura T. Usefulness of serum microRNA as a predictive marker of recurrence and prognosis in biliary tract cancer after radical surgery. Sci Rep 2019;9:5925. [PMID: 30976046 DOI: 10.1038/s41598-019-42392-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
103 Wang YF, Feng FL, Zhao XH, Ye ZX, Zeng HP, Li Z, Jiang XQ, Peng ZH. Combined detection tumor markers for diagnosis and prognosis of gallbladder cancer. World J Gastroenterol 2014; 20(14): 4085-4092 [PMID: 24744600 DOI: 10.3748/wjg.v20.i14.4085] [Cited by in CrossRef: 54] [Cited by in F6Publishing: 45] [Article Influence: 7.7] [Reference Citation Analysis]
104 Ku D, Tang R, Pang T, Pleass H, Richardson A, Yuen L, Lam V. Survival outcomes of hepatic resections in Bismuth-Corlette type IV cholangiocarcinoma. ANZ J Surg 2020;90:1604-14. [PMID: 31840387 DOI: 10.1111/ans.15531] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Wirasorn K, Ngamprasertchai T, Khuntikeo N, Pakkhem A, Ungarereevittaya P, Chindaprasirt J, Sookprasert A. Adjuvant chemotherapy in resectable cholangiocarcinoma patients. J Gastroenterol Hepatol. 2013;28:1885-1891. [PMID: 23829232 DOI: 10.1111/jgh.12321] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
106 Wu Z, Boonmars T, Nagano I, Boonjaraspinyo S, Pinlaor S, Pairojkul C, Chamgramol Y, Takahashi Y. Alteration of galectin-1 during tumorigenesis of Opisthorchis viverrini infection-induced cholangiocarcinoma and its correlation with clinicopathology. Tumour Biol 2012;33:1169-78. [PMID: 22373585 DOI: 10.1007/s13277-012-0360-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
107 Ota Y, Matsuyama R, Taniguchi K, Ueda M, Takeda K, Tanaka K, Nakayama T, Endo I. Solitary rib recurrence of hilar cholangiocarcinoma 10 years after resection: report of a case. Clin J Gastroenterol 2013;6:485-9. [PMID: 24319501 DOI: 10.1007/s12328-013-0432-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
108 Aktas G, Kus T, Metin T, Kervancioglu S, Elboga U. Long-term survival with transarterial chemoembolization and radioembolization in a patient with cancers of unknown primary. Onco Targets Ther 2018;11:1885-9. [PMID: 29670363 DOI: 10.2147/OTT.S153122] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
109 Schicho A, Pereira PL, Pützler M, Michalik K, Albrecht T, Nolte-Ernsting C, Stroszczynski C, Wiggermann P. Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in Intrahepatic Cholangiocellular Carcinoma (ICC): Results from a National Multi-Center Study on Safety and Efficacy. Med Sci Monit 2017;23:796-800. [PMID: 28192388 DOI: 10.12659/msm.902901] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
110 Brito AF, Ribeiro M, Abrantes AM, Mamede AC, Laranjo M, Casalta-Lopes JE, Gonçalves AC, Sarmento-Ribeiro AB, Tralhão JG, Botelho MF. New Approach for Treatment of Primary Liver Tumors: The Role of Quercetin. Nutr Cancer 2016;68:250-66. [PMID: 26943884 DOI: 10.1080/01635581.2016.1145245] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 6.0] [Reference Citation Analysis]
111 Zacharoulis D, Lazoura O, Sioka E, Potamianos S, Tzovaras G, Nicholls J, Koukoulis G, Habib N. Habib EndoHPB: a novel endobiliary radiofrequency ablation device. An experimental study. J Invest Surg. 2013;26:6-10. [PMID: 23273142 DOI: 10.3109/08941939.2012.681832] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
112 Ni Q, Wang H, Zhang Y, Qian L, Chi J, Liang X, Chen T, Wang J. MDCT assessment of resectability in hilar cholangiocarcinoma. Abdom Radiol (NY). 2017;42:851-860. [PMID: 27770159 DOI: 10.1007/s00261-016-0943-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
113 Wang Y, Cui W, Fan W, Zhang Y, Yao W, Huang K, Li J. Percutaneous intraductal radiofrequency ablation in the management of unresectable Bismuth types III and IV hilar cholangiocarcinoma. Oncotarget 2016;7:53911-20. [PMID: 27322076 DOI: 10.18632/oncotarget.10116] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
114 Shigehara K, Yokomuro S, Ishibashi O, Mizuguchi Y, Arima Y, Kawahigashi Y, Kanda T, Akagi I, Tajiri T, Yoshida H, Takizawa T, Uchida E. Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One. 2011;6:e23584. [PMID: 21858175 DOI: 10.1371/journal.pone.0023584] [Cited by in Crossref: 93] [Cited by in F6Publishing: 91] [Article Influence: 9.3] [Reference Citation Analysis]
115 Feng F, Cao X, Liu X, Qin J, Zhang S, Li Q, Liu J. Laparoscopic resection for Bismuth type III and IV hilar cholangiocarcinoma: How to improve the radicality without direct palpation. J Surg Oncol 2019;120:1379-85. [PMID: 31691290 DOI: 10.1002/jso.25739] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
116 Lim CS, Jang JY, Lee SE, Kang MJ, Kim SW. Reappraisal of hepatopancreatoduodenectomy as a treatment modality for bile duct and gallbladder cancer. J Gastrointest Surg. 2012;16:1012-1018. [PMID: 22271243 DOI: 10.1007/s11605-012-1826-5] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
117 Park KW, Jung ES, Kim DG, Yoo YK, Hong TH, Lee IS, Koh YH, Kim JH, Lee MA. ERCC1 Can Be a Prognostic Factor in Hilar Cholangiocarcinoma and Extrahepatic Bile Duct Cancer, But Not in Intrahepatic Cholangiocarcinoma. Cancer Res Treat. 2013;45:63-69. [PMID: 23613672 DOI: 10.4143/crt.2013.45.1.63] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
118 Pracht M, Le Roux G, Sulpice L, Mesbah H, Manfredi S, Audrain O, Boudjema K, Raoul JL, Boucher E. Chemotherapy for inoperable advanced or metastatic cholangiocarcinoma: retrospective analysis of 78 cases in a single center over four years. Chemotherapy. 2012;58:134-141. [PMID: 22572213 DOI: 10.1159/000337289] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
119 Lamarca A, Edeline J, McNamara MG, Hubner RA, Nagino M, Bridgewater J, Primrose J, Valle JW. Current standards and future perspectives in adjuvant treatment for biliary tract cancers. Cancer Treat Rev. 2020;84:101936. [PMID: 31986437 DOI: 10.1016/j.ctrv.2019.101936] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 11.5] [Reference Citation Analysis]
120 Chen YJ, Luo J, Yang GY, Yang K, Wen SQ, Zou SQ. Mutual regulation between microRNA-373 and methyl-CpG-binding domain protein 2 in hilar cholangiocarcinoma. World J Gastroenterol 2012; 18(29): 3849-3861 [PMID: 22876037 DOI: 10.3748/wjg.v18.i29.3849] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
121 Yu Y, Chen Y, Ma J, Yu X, Yu G, Li Z. SPARCL1 is a novel predictor of tumor recurrence and survival in hilar cholangiocarcinoma. Tumour Biol 2016;37:4159-67. [PMID: 26490986 DOI: 10.1007/s13277-015-4206-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
122 Anderson MA, Appalaneni V, Ben-menachem T, Decker GA, Early DS, Evans JA, Fanelli RD, Fisher DA, Fisher LR, Fukami N, Hwang JH, Ikenberry SO, Jain R, Jue TL, Khan K, Krinsky ML, Malpas PM, Maple JT, Sharaf RN, Shergill AK, Dominitz JA, Cash BD. The role of endoscopy in the evaluation and treatment of patients with biliary neoplasia. Gastrointestinal Endoscopy 2013;77:167-74. [DOI: 10.1016/j.gie.2012.09.029] [Cited by in Crossref: 68] [Cited by in F6Publishing: 47] [Article Influence: 8.5] [Reference Citation Analysis]
123 Dokduang H, Techasen A, Namwat N, Khuntikeo N, Pairojkul C, Murakami Y, Loilome W, Yongvanit P. STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression. J Hepatobiliary Pancreat Sci. 2014;21:767-776. [PMID: 25044480 DOI: 10.1002/jhbp.131] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
124 Kim JH, Won HJ, Shin YM, Kim KA, Kim PN. Radiofrequency ablation for the treatment of primary intrahepatic cholangiocarcinoma. AJR Am J Roentgenol. 2011;196:W205-W209. [PMID: 21257864 DOI: 10.2214/ajr.10.4937] [Cited by in Crossref: 114] [Cited by in F6Publishing: 57] [Article Influence: 11.4] [Reference Citation Analysis]
125 Sugita R. Magnetic resonance evaluations of biliary malignancy and condition at high-risk for biliary malignancy: Current status. World J Hepatol 2013; 5(12): 654-665 [PMID: 24432183 DOI: 10.4254/wjh.v5.i12.654] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
126 Takakura K, Kajihara M, Iwasaki T, Ide D, Miyazaki T, Arai Y, Saruta M, Arihiro S, Matsuoka M, Koido S, Ito R, Matsumoto M, Gocho T, Wakiyama S, Yanaga K, Tajiri H. Unusual images of mass-forming intrahepatic cholangiocarcinoma. Case Rep Gastroenterol 2013;7:414-9. [PMID: 24163655 DOI: 10.1159/000352015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
127 Kuang D, Wang G. Hilar cholangiocarcinoma: Pathology and tumor biology. Front Med China 2010;4:371-7. [DOI: 10.1007/s11684-010-0130-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
128 Huang GL, Luo Q, Rui G, Zhang W, Zhang QY, Chen QX, Shen DY. Oncogenic activity of retinoic acid receptor γ is exhibited through activation of the Akt/NF-κB and Wnt/β-catenin pathways in cholangiocarcinoma. Mol Cell Biol. 2013;33:3416-3425. [PMID: 23798555 DOI: 10.1128/mcb.00384-13mcb.00384-13] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Xiaofang L, Kun T, Shaoping Y, Zaiqiu W, Hailong S. Correlation between promoter methylation of p14(ARF), TMS1/ASC, and DAPK, and p53 mutation with prognosis in cholangiocarcinoma. World J Surg Oncol. 2012;10:5. [PMID: 22230750 DOI: 10.1186/1477-7819-10-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
130 Cwinn M, Walsh G, Rahman SH, Molinari M. The Geography of Primary Hepatic Neoplasms Treatments in Canada: Changes in Latitudes and Changes in Attitudes. Can J Gastroenterol Hepatol 2017;2017:9365657. [PMID: 28815170 DOI: 10.1155/2017/9365657] [Reference Citation Analysis]
131 Petrowsky H, Hong JC. Current surgical management of hilar and intrahepatic cholangiocarcinoma: the role of resection and orthotopic liver transplantation. Transplant Proc. 2009;41:4023-4035. [PMID: 20005336 DOI: 10.1016/j.transproceed.2009.11.001] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 4.0] [Reference Citation Analysis]
132 Gatto M, Bragazzi MC, Semeraro R, Napoli C, Gentile R, Torrice A, Gaudio E, Alvaro D. Cholangiocarcinoma: Update and future perspectives. Digestive and Liver Disease 2010;42:253-60. [DOI: 10.1016/j.dld.2009.12.008] [Cited by in Crossref: 123] [Cited by in F6Publishing: 111] [Article Influence: 11.2] [Reference Citation Analysis]
133 Rossignoli G, Grottesi A, Bisello G, Montioli R, Borri Voltattorni C, Paiardini A, Bertoldi M. Cysteine 180 Is a Redox Sensor Modulating the Activity of Human Pyridoxal 5'-Phosphate Histidine Decarboxylase. Biochemistry 2018;57:6336-48. [PMID: 30346159 DOI: 10.1021/acs.biochem.8b00625] [Reference Citation Analysis]
134 Yang H, Zhou J, Wei X, Wang F, Zhao H, Li E. Survival outcomes and progonostic factors of extrahepatic cholangiocarcinoma patients following surgical resection: Adjuvant therapy is a favorable prognostic factor. Mol Clin Oncol 2014;2:1069-75. [PMID: 25279199 DOI: 10.3892/mco.2014.377] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
135 Brito AF, Abrantes AM, Teixo R, Pires AS, Ribeiro AC, Ferreira RF, Mascarenhas A, Puga T, Laranjo M, Caramelo F, Boin I, Jefferson DM, Gonçalves C, Martins R, Tavares I, Ribeiro IP, Sarmento-Ribeiro AB, Carreira IM, Souza D, Tralhão JG, Botelho MF. Iodine‑131 metabolic radiotherapy leads to cell death and genomic alterations through NIS overexpression on cholangiocarcinoma. Int J Oncol 2020;56:709-27. [PMID: 31922240 DOI: 10.3892/ijo.2020.4957] [Reference Citation Analysis]
136 Feliu J, Sastre J, Maurel J, Isla D. Hepatocellular and biliary tract carcinomas: SEOM clinical guidelines. Clin Transl Oncol 2011;13:536-44. [PMID: 21821487 DOI: 10.1007/s12094-011-0694-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
137 Ahn KS, Kang KJ, Kang YN, Kim YH, Kim TS. Confinement to the intrapancreatic bile duct is independently associated with a better prognosis in extrahepatic cholangiocarcinoma. BMC Gastroenterol 2016;16:21. [PMID: 26911927 DOI: 10.1186/s12876-016-0444-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
138 Xu Y, Jiang X, Cui Y. Upregulated long noncoding RNA PANDAR predicts an unfavorable prognosis and promotes tumorigenesis in cholangiocarcinoma. Onco Targets Ther 2017;10:2873-83. [PMID: 28652769 DOI: 10.2147/OTT.S137044] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
139 Lee Y, Choi D, Han S, Han IW, Heo JS, Choi SH. Comparison analysis of left-side versus right-side resection in bismuth type III hilar cholangiocarcinoma. Ann Hepatobiliary Pancreat Surg 2018;22:350-8. [PMID: 30588526 DOI: 10.14701/ahbps.2018.22.4.350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
140 Francis H, DeMorrow S, Venter J, Onori P, White M, Gaudio E, Francis T, Greene JF Jr, Tran S, Meininger CJ, Alpini G. Inhibition of histidine decarboxylase ablates the autocrine tumorigenic effects of histamine in human cholangiocarcinoma. Gut 2012;61:753-64. [PMID: 21873469 DOI: 10.1136/gutjnl-2011-300007] [Cited by in Crossref: 48] [Cited by in F6Publishing: 100] [Article Influence: 4.8] [Reference Citation Analysis]
141 Xu Y, Yao Y, Jiang X, Zhong X, Wang Z, Li C, Kang P, Leng K, Ji D, Li Z, Huang L, Qin W, Cui Y. SP1-induced upregulation of lncRNA SPRY4-IT1 exerts oncogenic properties by scaffolding EZH2/LSD1/DNMT1 and sponging miR-101-3p in cholangiocarcinoma. J Exp Clin Cancer Res 2018;37:81. [PMID: 29642935 DOI: 10.1186/s13046-018-0747-x] [Cited by in Crossref: 85] [Cited by in F6Publishing: 93] [Article Influence: 28.3] [Reference Citation Analysis]
142 Mahadevan A, Dagoglu N, Mancias J, Raven K, Khwaja K, Tseng JF, Ng K, Enzinger P, Miksad R, Bullock A, Evenson A. Stereotactic Body Radiotherapy (SBRT) for Intrahepatic and Hilar Cholangiocarcinoma. J Cancer. 2015;6:1099-1104. [PMID: 26516357 DOI: 10.7150/jca.13032] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 9.0] [Reference Citation Analysis]
143 Likhitrattanapisal S, Kumkate S, Ajawatanawong P, Wongprasert K, Tohtong R, Janvilisri T. Dysregulation of microRNA in cholangiocarcinoma identified through a meta-analysis of microRNA profiling. World J Gastroenterol 2020; 26(29): 4356-4371 [PMID: 32848339 DOI: 10.3748/wjg.v26.i29.4356] [Reference Citation Analysis]
144 Kuhlmann JB, Euringer W, Spangenberg HC, Breidert M, Blum HE, Harder J, Fischer R. Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol. 2012;24:437-443. [PMID: 22261548 DOI: 10.1097/meg.0b013e3283502241] [Cited by in Crossref: 10] [Cited by in F6Publishing: 42] [Article Influence: 1.1] [Reference Citation Analysis]
145 Mohamadnejad M, DeWitt JM, Sherman S, LeBlanc JK, Pitt HA, House MG, Jones KJ, Fogel EL, McHenry L, Watkins JL, Cote GA, Lehman GA, Al-Haddad MA. Role of EUS for preoperative evaluation of cholangiocarcinoma: a large single-center experience. Gastrointest Endosc. 2011;73:71-78. [PMID: 21067747 DOI: 10.1016/j.gie.2010.08.050] [Cited by in Crossref: 131] [Cited by in F6Publishing: 105] [Article Influence: 11.9] [Reference Citation Analysis]
146 Ma K, Wei X, Dong D, Wu Y, Geng Q, Li E. PD-L1 and PD-1 expression correlate with prognosis in extrahepatic cholangiocarcinoma. Oncol Lett. 2017;14:250-256. [PMID: 28693161 DOI: 10.3892/ol.2017.6105] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
147 Song SC, Choi DW, Kow AW, Choi SH, Heo JS, Kim WS, Kim MJ. Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre. ANZ J Surg. 2013;83:268-274. [PMID: 22943422 DOI: 10.1111/j.1445-2197.2012.06195.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 95] [Article Influence: 5.2] [Reference Citation Analysis]
148 Lee KW, Lee JM, Choi HS, Kim ES, Keum B, Seo YS, Jeen YT, Um SH, Lee HS, Chun HJ, Kim CD, Oh CH, Kim HB. Novel Ablation Therapy Using Endoscopic Irreversible Electroporation in the Bile Duct: A Pilot Animal Study. Clin Endosc 2021;54:413-9. [PMID: 33076633 DOI: 10.5946/ce.2020.126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
149 Xu Y, Yao Y, Leng K, Li Z, Qin W, Zhong X, Kang P, Wan M, Jiang X, Cui Y. Long non-coding RNA UCA1 indicates an unfavorable prognosis and promotes tumorigenesis via regulating AKT/GSK-3β signaling pathway in cholangiocarcinoma. Oncotarget 2017;8:96203-14. [PMID: 29221199 DOI: 10.18632/oncotarget.21884] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 7.0] [Reference Citation Analysis]
150 Alvaro D, Cannizzaro R, Labianca R, Valvo F, Farinati F, Italian Society of Gastroenterology (SIGE), Italian Association of Hospital Gastroenterology (AIGO), Italian Association of Medical Oncology (AIOM), Italian Association of Oncological Radiotherapy (AIRO). Cholangiocarcinoma: A position paper by the Italian Society of Gastroenterology (SIGE), the Italian Association of Hospital Gastroenterology (AIGO), the Italian Association of Medical Oncology (AIOM) and the Italian Association of Oncological Radiotherapy (AIRO). Dig Liver Dis. 2010;42:831-838. [PMID: 20702152 DOI: 10.1016/j.dld.2010.06.005] [Cited by in Crossref: 23] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
151 Chen Y, Luo J, Tian R, Sun H, Zou S. miR-373 negatively regulates methyl-CpG-binding domain protein 2 (MBD2) in hilar cholangiocarcinoma. Dig Dis Sci 2011;56:1693-701. [PMID: 21086164 DOI: 10.1007/s10620-010-1481-1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 3.7] [Reference Citation Analysis]
152 Collins AL, Wojcik S, Liu J, Frankel WL, Alder H, Yu L, Schmittgen TD, Croce CM, Bloomston M. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma. Ann Surg Oncol 2014;21:133-8. [PMID: 24046106 DOI: 10.1245/s10434-013-3240-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.9] [Reference Citation Analysis]
153 Hamada S, Satoh K, Hirota M, Kanno A, Ishida K, Umino J, Ito H, Kikuta K, Kume K, Masamune A, Katayose Y, Unno M, Shimosegawa T. Calcium-binding protein S100P is a novel diagnostic marker of cholangiocarcinoma. Cancer Sci. 2011;102:150-156. [PMID: 21029254 DOI: 10.1111/j.1349-7006.2010.01757.x] [Cited by in Crossref: 40] [Cited by in F6Publishing: 36] [Article Influence: 3.6] [Reference Citation Analysis]
154 Moole H, Dharmapuri S, Duvvuri A, Dharmapuri S, Boddireddy R, Moole V, Yedama P, Bondalapati N, Uppu A, Yerasi C. Endoscopic versus Percutaneous Biliary Drainage in Palliation of Advanced Malignant Hilar Obstruction: A Meta-Analysis and Systematic Review. Can J Gastroenterol Hepatol 2016;2016:4726078. [PMID: 27648439 DOI: 10.1155/2016/4726078] [Cited by in Crossref: 32] [Cited by in F6Publishing: 22] [Article Influence: 6.4] [Reference Citation Analysis]
155 孙诚谊, 江建新. 肝门部胆管癌的外科治疗. 世界华人消化杂志 2011; 19(8): 771-776 [DOI: 10.11569/wcjd.v19.i8.771] [Reference Citation Analysis]
156 Lee SM, Ko HK, Shin JH, Kim JH, Chu HH. Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival. Diagn Interv Radiol 2020;26:45-52. [PMID: 31904570 DOI: 10.5152/dir.2019.18552] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
157 Matos C, Serrao E, Bali MA. Magnetic resonance imaging of biliary tumors. Magn Reson Imaging Clin N Am. 2010;18:477-496. [PMID: 21094451 DOI: 10.1016/j.mric.2010.08.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]